Table 5.
Effects of inter-person differences and within-person changes in TRAb levels on clinical characteristics: subgroup analysis of patients with active TED at baseline (n=25)
| Variables | Effect of TSI on clinical characteristics | |
| Estimated change (SE) | P value* | |
| CAS | ||
| Inter-person | −0.0002 (0.0020) | 0.9347 |
| Within-person | 0.0046 (0.0016) | 0.0064 |
| NOSPECS | ||
| Inter-person | 0.0014 (0.0031) | 0.6559 |
| Within-person | 0.0034 (0.0016) | 0.0385 |
| Proptosis | ||
| Inter-person | 0.0016 (0.0070) | 0.8178 |
| Within-person | 0.0014 (0.0018) | 0.4464 |
| Variables | Effect of TBII on clinical characteristics | |
| Estimated change (SE) | P value* | |
| CAS | ||
| Inter-person | 0.0470 (0.0146) | 0.0023 |
| Within-person | 0.0243 (0.0284) | 0.3959 |
| NOSPECS | ||
| Inter-person | 0.0517 (0.0245) | 0.0402 |
| Within-person | 0.0397 (0.0261) | 0.1354 |
| Proptosis | ||
| Inter-person | 0.1067 (0.0566) | 0.0657 |
| Within-person | −0.0046 (0.0290) | 0.8742 |
*P values were calculated using a linear mixed model with time-dependent covariates adjusted for age, sex, smoking status and treatment modality. Numbers in bold denote statistically significant changes.
CAS, clinical activity score; NOSPECS, no signs or symptoms, only signs, soft tissue involvement, proptosis, extraocular muscle involvement, corneal involvement, sight loss; TBII, thyroid-stimulating hormone receptor-binding inhibitory immunoglobulin; TED, thyroid eye disease; TRAb, thyroid-stimulating hormone receptor antibody; TSI, thyroid-stimulating immunoglobulin.